Equity Method of Accounting for Common Stock of Oncocyte, at Fair Value - Schedule of Condensed Results of Operations and Balance sheet Information (Details) - OncoCyte Corporation [Member] - USD ($) $ in Thousands		2 Months Ended		12 Months Ended
		Feb. 16, 2017	[1]	Dec. 31, 2018	Dec. 31, 2017
Research and development expense		$ 798		$ 6,506	$ 7,174
General and administrative expense		377		6,153	9,232
Sales and marketing expense		213		1,681	2,443
Loss from operations		(1,388)		(14,340)	(18,849)
Net loss		$ (1,392)		(14,890)	(19,375)
Current assets	[2]			8,642	8,528
Noncurrent assets	[2]			876	1,688
Total assets	[2]			9,518	10,216
Current liabilities	[2]			4,698	4,454
Noncurrent liabilities	[2]			534	1,359
Stockholders' equity	[2]			4,286	4,403
Total liabilities and stockholders' equity	[2]			$ 9,518	$ 10,216

[1] OncoCyte's condensed results of operations for the period from January 1, 2017 through February 16, 2017, the date immediately preceding the OncoCyte Deconsolidation, for the year ended December 31, 2017, shown in the table below, is included in the consolidated results of operations of BioTime, after intercompany eliminations, as applicable.

[2] The condensed balance sheet information of OncoCyte as of December 31, 2018 and 2017, is provided for informational and comparative purposes only. OncoCyte was not included in BioTime's consolidated balance sheet as of December 31, 2018 and 2017 due to the OncoCyte Deconsolidation on February 17, 2017.